Callan Family Office LLC Buys Shares of 6,183 Biogen Inc. $BIIB

Key Points

• Callan Family Office acquired 6,183 Biogen shares during the second quarter, valued at approximately $1.34 million. Several other institutional investors also initiated positions, and institutions collectively own 87.93% of Biogen’s stock.
• Biogen reported quarterly earnings of $3.60 per share, exceeding the $2.94 consensus estimate, while revenue reached $2.74 billion and increased 3.4% year over year.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $227.07, compared with the stock’s reported price of $216.78.

Callan Family Office LLC purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 6,183 shares of the biotechnology company's stock, valued at approximately $1,336,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Keebeck Wealth Management acquired a new stake in shares of Biogen in the 2nd quarter worth approximately $301,000. Keating Financial Advisory Services Inc. acquired a new position in Biogen during the second quarter worth $58,000. Encore Global Management LP purchased a new stake in Biogen during the second quarter worth $108,000. Allworth Financial LP purchased a new stake in Biogen during the second quarter worth $1,736,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new stake in Biogen in the second quarter valued at $2,648,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Price Performance

BIIB opened at $216.78 on Monday. The firm has a market cap of $32.03 billion, a P/E ratio of 38.37, a PEG ratio of 6.75 and a beta of 0.17. The business's fifty day simple moving average is $205.53 and its 200 day simple moving average is $194.58. Biogen Inc. has a 52 week low of $131.52 and a 52 week high of $222.15. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BIIB has been the subject of several research reports. Weiss Ratings downgraded Biogen from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, August 12th. Evercore began coverage on shares of Biogen in a research note on Friday, May 15th. They issued an "outperform" rating on the stock. Citigroup raised their target price on shares of Biogen from $200.00 to $215.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Barclays upped their price target on shares of Biogen from $185.00 to $200.00 and gave the company an "equal weight" rating in a report on Wednesday, July 29th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Biogen in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $227.07.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source